
Ming Zheng
Vice President of Clinical Science and 
    Medical Affairs
    Shanghai MicroPort Medical (Group) Co., Ltd.

Xiaoming Feng
Researcher
    National Institutes for Food and 
    Drug Control

YUZELI
RAC, Global
    YUZELI MEDTECCONSULTANT INC.

Yongqiang Hao
Chief Physician
    Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine

Alex Jiang
Quality Director of APAC
    Smith & Nephew

Andy Yin
R&D director
    Shanghai Innovation and R&D Center of Blue Sail Medical

Xiangdan Kim
Global Regulatory Affairs Expert
    Lepu Medical Technology
(Beijing)Co.,Ltd.

Lane JI
Medical Devices Director of BSI China
    BS

Tamara Yuan
APAC QA/QC VP
    Zimmer Biomet Inc.

Li Shen
Director of Cardiovascular
    Secretary-General of CCI 
    Zhongshan Hospital Affiliated to Fudan University

Yulin Weng
Founder and CEO
    DK MEDTECH

Ben Zhao
Senior Reliability Engineer
    Medtronic,China R&D Center

Jian Fong TAN
Chief Technology Officer
    Peijia Medical Limited

Cheng Yunzhang
Vice President, School of Medical Instrument 
    and Food Engineering, University of Shanghai 
    for Science and Technology (USST) 
    Director of Shanghai Interventional Medical 
    Device Engineering Technology Research Center

Jack Li
CTO
    Shanghai HeartCare Medical 
    Technology Co., Ltd

Zikai Hua
Director of Intelligent Components Research 
    Center, Shanghai University
    Director of Orthotek Lab of Shanghai University

Thomas Row
Sr. Industrial Designer 
    Medtronic Technology Center, Shanghai

Pengfei Yang
Deputy director of cerebrovascular 
    disease center
    Changhai Hospital of The Second 
    Military Medical University

Hongfeng Ju
General Manager
    WEGO

Guangmei Wu
Director of 3D Printing Asia Programs
    Johnson & Johnson

Caimei Wang
Director of R&D Center
    Beijing AK Medical Co., Ltd.

Jack Zhou
Chief Operating Officer
    DiNova-Hangzhou Wei Qiang Medical 
    Technology Co., Ltd.

Sean Kang
General Manager 
    Sino Shenchang Medical Technology Co., Ltd.

Xuanyong Liu
Researcher, Director of Biomaterials and 
    Tissue Engineering Research Center
    Shanghai Institute of Ceramics, 
    Chinese Academy of Sciences

Ke Yang
Researcher
    Institute of metal research,
    Chinese Academy of Sciences

Daxin Wen
Sales Engineer
    Coherent (Beijing) Commercial Co.,Ltd

Shen Liu
Head of Medical Industry
    GF Machining Solutions

Alex Han
Product Sales Manager
    Carl Zeiss Shanghai Co.,Ltd

Jeff Zhang
Lab Weighing Application Specialist
    Sartorius

Lynn Jiao
Vice President & 
    China Executive Director
    Advanced Medical Technology 
    Association (AdvaMed)
 
 
Xiaoming Feng
    Researcher
    National Institutes for Food and Drug Control
Registration and Inspection of Medical Devices 
    under the New Regulations
To innovate medical device products, we should pay attention to inspection methods and research. Why? Because for many innovative medical devices, there is no standards to follow, and the inspection methods are uncertain or absent, it is necessary to do research on inspection methods and inspection methodologies while innovating medical devices. For personalized and customized products, I can't use this product for destructive inspection, which will destroy the product. Correct inspection should pay more attention to our product quality control in the middle stage of the processing process. Also, we may pay more attention to rapid inspection methods as it is impossible for us to use some slow inspection methods, which require to wait for the inspection results before we release them, so we need to do some online inspection and rapid inspection methods.
 
Hong Qian
    Minister
    Center for Drug Certification and Evaluation
    Shanghai Municipal Food and Drug Administration
Analysis if medical device technical review-
    related policies and common issues
Since June 1, the newly revised Regulations on the Supervision and Administration of Medical Devices has been officially implemented, and it once again emphasizes the quality management of medical devices in the whole life cycle. The registrant or filer is responsible for the safety and effectiveness of medical devices in the whole process of development, production, operation and use according to law. As for the self-test report, it is the most basic requirement that the information submitted should be legal, true, accurate, complete and traceable. In terms of innovation, China encourages innovation greatly, formulates medical device industry plans and policies, and gives priority to the review and approval of innovative products. China shall improve the innovation system of medical devices and support some basic research and applied research of our medical devices, including the promotion and application of new products.
 
Ming Zheng
    Vice President of Clinical Science and Medical Affairs
    Shanghai MicroPort Medical (Group) Co., Ltd.
Global planning and layout of clinical trials and leadership in science 
    for medical device companies with China joining the ICH
If you want to join ICH, this is a better opportunity, and also there are many challenges at the same time. Only when you go abroad can you become stronger and become a better enterprise. Second, the international layout of clinical trials comes with overall layout and individual layout, that is to say, this layout should follow many principles, for example, what is the clinical path, and achieving scientific top-level design, so that medical devices can successfully cope with the market. Third, the layout of scientific leadership for core products should be carried out simultaneously, because this is a very high and wide moat. If you have a good layout of this moat, it will be very fast to improve the products and global leadership of the company, especially such a very core and very effective one.
 
Jack Li
    CTO
    Shanghai HeartCare Medical Technology Co., Ltd
Future Is Now:
    Development of Innovative Interventional Treatment of Stroke
The volume of devices for embolization treatment, stenosis treatment, prevention and bleeding treatment is very large. If we calculate this volume according to the current market price and the devices sold in the market, by 2025, the volume of devices for embolization thrombectomy and aspiration will be about 13 billion, and the volume of devices for stenosis treatment will be about 2.4 billion, which should actually be more than that. In terms of prevention, the devices are mainly used for atrial fibrillation and left atrial appendage occlusion, seemingly 2 billion at present. In fact, due to the influence of medical insurance, devices for left atrial appendage occlusion have not really been popularized, and those for coronary artery and cranial nerve are not well combined. There is still a long way to go before this prevention could really be carried out well. In terms of bleeding, coils are old products, with a scale of about 9 billion, and there will be large space for growth in the future.
 
Jian Fong TAN
    Chief Technology Officer
    Peijia Medical Limited
Transcatheter Technologies for Structural Heart:
    Repair or Replacement?
Should mitral valve be replaced or repaired? Five years ago, it must have been a replacement, but now there are many people who are optimistic about repair. This is a dynamic situation. Today, five years later, is a different situation, depending on what direction the next equipment research and development is. If we answer the question on tricuspid valve, should it be replaced or repaired? This is even harder to answer. The answer may intend to be repair, just a little. It may not be such a situation in five years, but at least now I personally think it is such a situation. To sum up, to 
    repair or replace, we need to judge whether it is aortic valve or mitral/tricuspid valve. Replacement is the mainstream in terms of aortic valve, and repair accounts for a large proportion in term of mitral valve, but we must never forget the importance of TMVR in replacement of mitral valve. After all, not all patients are suitable for clip surgery.
 
Hongfeng Ju
    General Manager
    WEGO
Thinking and Practice of Intelligent Manufacturing 
    Transformation in Medical Device Enterprises
We are followers of innovation, slowly transitioning to the leader of innovation, which is a great challenge for us. Based on the above challenge, we think there are two very important points: the first is the value orientation in the whole strategic management process, and the second is the creation of end-to-end data link, which is the strategy of digital transformation. For every medical enterprise, first, in the whole manufacturing management process, the effective unification of man and machine, including the management of production rhythm, moves toward from manufacturing 3.0 to manufacturing 4.0; second, the management of the enterprise itself and its stakeholders, including the upstream and downstream of the value chain; third, the production, supply and marketing of the enterprise itself, including three-level management and four-level management, and the value chain coordination within the group, which is very important.
 
Pengfei Yang
    Deputy director of cerebrovascular disease center
    Changhai Hospital of The Second Military Medical University
Innovation in clinical trials and neurointerventional devices
I think nerve intervention can account for one fifth of the future nerve intervention now. We must find out where the next potential point is and who will explore this point? Clinicians shoulder a great mission. When we explore this point, I think the business community has invested more in all aspects. Of course, how can you innovate? Subversive innovation - doctors should participate in subversive innovation-is the point that you find, and then firmly do clinical trials towards while making subversive product research and development, which is the real subversive innovation. I don't mean that this will work. I just tell you, as clinicians, what are our thoughts on medical device innovation? What we have to do is to expand the scope of our industry.